论文部分内容阅读
目的研究奥扎格雷钠应用于肺源性心脏病(肺心病)急性加重期高凝状态的治疗效果。方法 86例肺心病急性加重期患者,将其随机分为对照组与观察组,各43例。对照组实施常规治疗,观察组在对照组基础上给予奥扎格雷钠治疗。观察两组患者治疗后的临床效果、凝血因子水平以及血气分析情况。结果观察组治疗后的总有效率为93.02%,高于对照组的72.09%,差异有统计学意义(P<0.05)。观察组的6-酮-前列腺素F_1α水平为(34.52±6.78)ng/L,血栓素B_2水平为(150.62±20.15)ng/L,氧分压为(9.89±0.76)kPa,二氧化碳分压为(6.37±1.26)kPa,均优于对照组的(24.14±7.06)ng/L、(178.39±25.24)ng/L、(8.31±0.65)kPa和(7.62±1.09)kPa,差异有统计学意义(P<0.05)。结论奥扎格雷钠应用于肺心病急性加重期的治疗中,能够明显控制疾病发展,改善高凝状态,值得临床推广。
Objective To study the therapeutic effect of ozagrel sodium on hypercoagulable state of acute exacerbation of pulmonary heart disease (pulmonary heart disease). Methods 86 cases of acute exacerbation of pulmonary heart disease patients, were randomly divided into control group and observation group, 43 cases in each. The control group was given routine treatment, and the observation group was treated with ozagrel sodium on the basis of the control group. After treatment, the clinical effects, clotting factor levels and blood gas analysis were observed. Results The total effective rate of the observation group after treatment was 93.02%, which was higher than that of the control group (72.09%), the difference was statistically significant (P <0.05). The level of 6-keto-prostaglandin F_1α in observation group was (34.52 ± 6.78) ng / L, the level of thromboxane B_2 was (150.62 ± 20.15) ng / L and the partial pressure of oxygen was (9.89 ± 0.76) kPa (6.37 ± 1.26) kPa were significantly higher than those in the control group (24.14 ± 7.06 ng / L, 178.39 ± 25.24 ng / L, 8.31 ± 0.65 kPa and 7.62 ± 1.09 kPa, respectively, with significant difference (P <0.05). Conclusion Ozagrel sodium used in the treatment of acute exacerbation of pulmonary heart disease, can significantly control the disease development, improve hypercoagulable state, worthy of clinical promotion.